

Bridging Two Worlds: The Application of High-Throughput Screening to Structural Chemistry

Elliot Dean

9 June 2018

Department of Microbiology



Department of Biochemistry and Biophysics

Perelman School of Medicine, University of Pennsylvania




Investigating The Role Of Secreted Factors During The Induction Of Therapy And Oncogene Induced Senescence

- Senescence is defined as a stable proliferation arrest, that can happen in many cell types
- Commonly, Senescence is thought of as a cellular response to uninhibited growth, as a type of tumor suppressive activity
- However, there are many aspects of Senescence that can negatively affect cells
- Finding ways to curb the detrimental aspects of Senescence while reinforcing the benefits is an ongoing area of research





What is Senescence?




Classifying Senescence: Gene Expression & Phenotypic Changes

Figure 1 qPCR results for gene changes from day 0 senescence to day 14

qPCR was performed on 5 different samples: uninfected melanocytes (day 0), and 4 BRAF^{V600E} melanocytes from 4 different time points (days 3, 7, 11, and 14). CT values were normalized between the GAPDH (a housekeeping gene) values of day 0 and the other samples. Once this ratio was obtained, the other genes were compared. The relative expression is the fold change in expression of that gene in the cell.




A Paradigm of Senescence: Overexpression of Cytokines



What Happens to Senescent Cells?

Senescence-associated secretory phenotype (SASP)



Finding Inhibitors for the Inflammation Response in Senescent Cells: Pilot Screen Compounds


- MLL is a histone methyltransferase involved in the global regulation of gene transcription. The MLL-Menin interaction allows aberrant, uncontrolled cell division. MI-503 and MI-2-2 inhibit this interaction
- QNZ (EVP4593) is a potent NF- κ B inhibitor. NF- κ B is linked to DNA transcription and cell survival. Changes in NF- κ B can lead to cancer and autoimmune disease
- Deoxycorticosterone and dexamethasone are both steroids that abate the inflammation response
- MGCD0103 and TSA are HDAC inhibitors, predicted to be tumor suppressors, due to their epigenetic effect on p21 and pRb
- Decitabine is a hypomethylating agent, inhibiting DNA synthesis

Drug Name	Target	FDA Approved	Indication	Concentration	Units	Box (AML)
MI-503	Menin		MLL leukemia	10	mM	8
MI-2-2	Menin		MLL leukemia	10	mM	8
QNZ (EVP4593)	NF- κ B			10	mM	8
Deoxycorticosterone	GluR	Y		10	mM	9
Dexamethasone Acetate	Glucocorticoid	Y		10	mM	4
MGCD0103	HDAC	Y	DLBCL	10	mM	4
Trichostatin A	HDAC			1	mM	own box
Decitabine	DNA synthesis	Y	AML	10	mM	4

Finding Inhibitors for the Inflammation Response in Senescent Cells: Experimental Design



- IMR-90 cells (fibroblasts) were used for cytokine expression
- 96 & 384 well plates allowed for high-throughput processing
- Cells were cultured up to PD-40, and split often to prevent high confluency
- DMSO concentration was kept at 0.5%. Negative effects seen in culture were negligible
- Media additions / aspirations, and compound addition were performed using a multidrop combi, Biotek x405, and Janus workstation (respectively)

Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8
Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday	Monday	Tuesday
	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	
Plate Cells	Etoposide /DMSO Treatment	Refeed Media + Compound				Serum-Free media change	Harvest supernatant/Assay




AlphaLISA Quantification of Cytokines:

Assay
Confirmation
+
Standardization




AlphaLISA Results – IL6: Compound VS Signal

Extended Drug Treatment IL6



AlphaLISA Results – IL8: Compound VS Signal

Extended Drug Treatment IL8



What is the bridge from HTS to Structural Chemistry at Penn?

Penn



EPIGENETICS INSTITUTE

A red stylized logo, similar in design to the blue one, consisting of overlapping curved shapes forming a circular, flower-like or DNA-helix-like structure.

- The UPenn Epigenetics Institute is a large group of researchers dedicated to working on epigenetics and age related diseases
- The two labs that I was a part of (HTS Core in Microbiology, Marmorstein Lab in Biochemistry) are integral to this collaboration


Purifying Proteins (a very long list)

- I have expressed (and for many, cloned) all of the listed proteins in *E. Coli* or SF9 cells
- Fast Protein Liquid Chromatography was utilized for these projects, employing techniques such as size exclusion, ion exchange, and affinity

- Rap1
- hMOF
- JAK2
- S6K2
- HIRA
- Complex
- DAXX

- HAT1
- BRAF
- MEK
- JADE1
- HBO1
- ACSS2


USER: 6.3
User: Default 9/6/2017 9:34:25 AM -07:00
Run By : Default 9/5/2017 3:34:30 PM -07:00
Result: hMOF5 001



hMOF HAT
domain
(174-449)
Purification
6
His Nickel
Affinity +
Gel filtration
FPLC
Coomassie
Gel



9/6/17

Purifying hMOF: A Relatively Straightforward Process



Application: Assays

- Thermal shift assays determine the melting temperature of a protein due to various factors
- These may include: pH, Salinity, Substrate / Protein Concentration
- The higher melting temperature observed relative to baseline indicates a stabilization of the protein (or protein / compound complex)
- The assay requires minimal resources – widely available reagents, cost effective, and accommodates high-throughput applications
- A qPCR machine measures fluorescence (a dye, SYPRO orange, is the origin) as the assay plate is heated
- Over time, the dye (which binds to hydrophobic surfaces) is exposed to the reaction buffer. Signal increases until max temperature is reached, and gradually diminishes



**Application:
Crystallize Protein**



X-Ray Diffraction




Data Analysis



**Solve Protein
Structure**





**Advance Human
Knowledge :D**



Structure of hMOF

a



c






Plate	Well	MAYBRIDGE CODE	MolFormula	MolWeight	Parent MolWt	Salt_Info	CATALOGUE_Ref	TARGET WEIGHT (mgs)	ACTUAL WEIGHT (mgs)	Smiles	Moles	Concentration	Units	MeOH_50mM	Units
1	A2	CC08110	C2 H Br N2 S	165.0139	165.01		CC08110FL	5	4.94	S1C(=NN=C1)Br	0.0000299	50 mM		599. uL	
1	B2	CC38510	C10 H12 Br N	226.1158	226.12		CC38510FL	5	4.96	N1(c2cccc(c2)Br)CCCC1	0.0000219	50 mM		439. uL	
1	C2	MO07325	C6 H7 Br N2 O2	219.0373	219.04		MO07325FL	5	5.05	N1(C(=CN=C1Br)C(=O)OC)C	0.0000230	50 mM		461. uL	
1	D2	AW00238	C13 H9 Br F3 N3 O S	392.198	392.19		AW00238SC	5	5.07	n1c(nccc1C(F)(F)F)SCC(=O)Nc1ccc(cc1)Br	0.0000129	50 mM		259. uL	
1	E2	AW00727	C12 H16 Br F N2	287.1744	287.17		AW00727FL	5	4.97	N1(Cc2c(cc(cc2)Br)F)CCCNCC1	0.0000173	50 mM		346. uL	
1	F2	AW00960	C14 H14 Br N O2	308.174	308.17		AW00960SC	5	5.08	N1(c2ccc(cc2)Br)C(=O)CC2(C1=O)CCCC2	0.0000164	50 mM		330. uL	
1	G2	BT000081	C20 H14 Br N O3	396.239	396.24		BT000081SC	5	5	N1C(=O)C(c2c1ccc(c2)Br)(CC(=O)c1ccc2ccccc2c1)O	0.0000126	50 mM		252. uL	
1	H2	BT000089	C18 H16 Br N O3	374.232	374.23		BT000089SC	5	5.08	N1C(=O)C(c2c1ccc(c2)Br)(CC(=O)c1c(c(cc1)C)C)O	0.0000139	50 mM		271. uL	
1	A3	BT000099	C13 H12 Br N O2	294.1468	294.15		BT000099SC	5	5.05	n1c2c(c(cc1C)C(=O)OCC)cc(cc2)Br	0.0000171	50 mM		343. uL	
1	B3	BT000115	C11 H10 Br N3 O	280.124	280.12		BT000115SC	5	4.92	n1c2c(c(cc1C)C(=O)NN)cc(cc2)Br	0.0000175	50 mM		351. uL	
1	C3	BT000244	C20 H14 Br N O3	396.239	396.24		BT000244SC	5	5.05	N1C(=O)C(c2c1ccc(c2)Br)(CC(=O)c1ccc2ccccc2c1)O	0.0000126	50 mM		252. uL	
1	D3	BT000245	C18 H16 Br N O3	374.232	374.23		BT000245SC	5	5.08	N1C(=O)C(c2c1ccc(c2)Br)(CC(=O)c1c(c(cc1)C)C)O	0.0000139	50 mM		271. uL	
1	E3	BT000246	C13 H12 Br N O2	294.1468	294.15		BT000246SC	5	5.05	n1c2c(c(cc1C)C(=O)OCC)cc(cc2)Br	0.0000171	50 mM		343. uL	
1	F3	BT000500	C11 H10 Br N3 O	280.124	280.12		BT000500SC	5	4.92	n1c2c(c(cc1C)C(=O)NN)cc(cc2)Br	0.0000175	50 mM		351. uL	
1	G3	BT000501	C20 H14 Br N O3	396.239	396.24		BT000501SC	5	5.05	N1C(=O)C(c2c1ccc(c2)Br)(CC(=O)c1ccc2ccccc2c1)O	0.0000126	50 mM		252. uL	
1	H3	BT000503	C18 H16 Br N O3	374.232	374.23		BT000503SC	5	5.08	N1C(=O)C(c2c1ccc(c2)Br)(CC(=O)c1c(c(cc1)C)C)O	0.0000139	50 mM		271. uL	
1	A4	BT000581	C13 H12 Br N O2	294.1468	294.15		BT000581SC	5	5.05	n1c2c(c(cc1C)C(=O)OCC)cc(cc2)Br	0.0000171	50 mM		343. uL	
1	B4	BT000681	C11 H10 Br N3 O	280.124	280.12		BT000681SC	5	4.92	n1c2c(c(cc1C)C(=O)NN)cc(cc2)Br	0.0000175	50 mM		351. uL	
1	C4	BT000694	C14 H14 Br N O2	308.174	308.17		BT000694SC	5	4.94	N1(c2ccc(cc2)Br)C(=O)CC2(C1=O)CCCC2	0.0000164	50 mM		330. uL	
1	D4	BT01061	C11 H7 Br O3	267.0773	267.08		BT01061SC	5	5.07	O1C(=O)C(=Cc2cc(ccc21)Br)C(=O)C	0.0000189	50 mM		380. uL	
1	E4	BT01179	C15 H15 Br N2 O3 S	383.264	383.26		BT01179SC	5	5	S(=O)(=O)(Nc1ccc(c(c1)N=Cc1cc(ccc1O)Br)C)C	0.0000130	50 mM		261. uL	
1	F4	BT01253	C10 H5 Br O4	269.0495	269.05		BT01253SC	5	4.94	O1C(=O)C(=Cc2c1ccc(c2)Br)C(=O)O	0.0000183	50 mM		367. uL	
1	G4	BT01338	C17 H17 Br N2 O4	393.235	393.24		BT01338SC	5	4.93	N(=Cc1cc(ccc1O)Br)N=Cc1cc(c(c1)OC)OC)OC	0.0000125	50 mM		251. uL	
1	H4	BT01340	C13 H9 Br N4 O	317.145	317.14		BT01340SC	5	4.91	N1=Nc2cc(ccc2N1)N=Cc1cc(ccc1O)Br	0.0000154	50 mM		310. uL	
1	A5	BT01804	C18 H14 Br N3 O2	384.232	384.23		BT01804SC	5	5	n1c2c(c(cc1C)C(=O)NN=Cc1c(cccc1O)cc(cc2)Br	0.0000130	50 mM		260. uL	
1	B5	BT01924	C7 H5 Br2 N O2	294.9295	294.93		BT01924SC	5	4.93	O=C(c1c(c(cc(c1)Br)Br)N)O	0.0000167	50 mM		334. uL	
1	C5	BT01928	C12 H9 Br2 N O2	359.016	359.02		BT01928SC	5	4.96	N1=C(C(OC(=O)c2ccc(cc21)Br)Br)C(=CC)C	0.0000138	50 mM		276. uL	
1	D5	BT01996	C12 H9 Br Cl N O3	330.564	330.56		BT01996SC	5	4.91	n1c2c(c(c(c1C)C(=O)OCC)O)cc(cc2Cl)Br	0.0000148	50 mM		297. uL	
1	E5	BT02039	C14 H8 Br Cl F3 N O	378.574	378.58		BT02039SC	5	4.98	N(=Cc1c(ccc(c1)Br)O)c1cc(ccc1Cl)C(F)(F)F	0.0000131	50 mM		263. uL	
1	F5	BT02093	C9 H6 Br N O2	240.055	240.06		BT02093SC	5	4.92	N1=C(C)OC(=O)c2cc(ccc12)Br	0.0000204	50 mM		410. uL	
1	G5	BT02228	C19 H18 Br N3 O2	400.274	400.27		BT02228SC	5	5.06	N1(c2c(cccc2)N2CCOCC2)C(=O)c2c(ccc(c2)Br)N=C1C	0.0000126	50 mM		253. uL	

Compound Library Management, Organization, and Usage


ACSS2: From acetyl-CoA Production to Histone Acetylation






ACSS2 Purification (Part I): Anion Exchange Chromatography

UNICORN 6.3
User: Default 5/26/2018 10:13:07 AM -07:00
Run By : Default 5/25/2018 4:20:08 PM -07:00
Result: acss2forrealis1anionexchange(636628620088932359)




Hs
ACSS2-30-701
codon
optimized
Purification 1
Talon nickel
affinity-->
Anion
Exchange
Coomassie gel




ACSS2 Purification (Part II): Size Exclusion Chromatography (S-200)

UNICORN 6.3
User: Default 5/26/2018 10:41:26 AM -07:00
Run By : Default 5/26/2018 12:52:25 PM -07:00
Result: acsa2forrealisa200runnumberuno52518 (636629359457861843)

1 (1)




Hs
ACSS2-30-701
codon
optimized
Purification 1
Anion
Exchange-->
Superdex 200
Coomassie gel
5/26/18




1-Fraction 20
2-Fraction 21
3-Fraction 22
4-Fraction 23
5-Fraction 24
6-MW Marker

ACSS2 Purification (Part III): Size Exclusion (Superdex 75)

User: Default 6/15/2018 10:33:30 AM -07:00
Run By : Default 6/14/2018 5:10:32 PM -07:00
Result: HsACSS2 s#9 30-701 s75 06-14-18 001



Hs
ACSS2-30-701
codon optimized
Purification 2
Superdex 75
Coomassie gel
6/14/18




Assaying for enzymatic activity: Quantifying production of acetyl-CoA from Acetate

Experiment:



Component	Volume/Well	Final []	For 20 reactions
10X Buffer	2.5 uL	1X	50 uL
5 mg/mL BSA	0.5 uL	0.1 mg/mL	10 uL
1 mM CoA	2.5 uL	100 uM	50 uL
1 mM ATP	0.5 uL	20 uM	10 uL
5X Enzyme (ACSS2)	5 uL	1X (calculate)	N/A
25 mM Acetate	5 uL	5 mM	100 uL
ddH ₂ O	9 uL	N/A	180 uL
Total	25 uL	N/A	400 uL

- 3-5 enzyme concentrations in triplicate
- Prepare 500 (more or less) nM diluted enzyme in assay buffer, prepare serial dilutions
- Prepare a master reaction mix minus enzyme
- Add 20 uL of reaction mix to white opaque bottom plate (corning 3570) using 16-ch pipette
- Add 5 uL of enzyme, manually
- Seal and Tap spin plate for 1 min at 300xg
- Incubate at room temp for 1-2 hrs
- Add 25uL of 1X ATPase
- Tap spin for 1 minute at 300xg
- Incubate for 5 minutes
- Read luminescence


Signal: vs. Name of sample:



Refining the Assay: Concentration + Incubation Time



Screening for ACS2 Inhibitors: It all comes down to this



Acknowledgements!



- Richmond Laboratory, Vanderbilt
 - Jeffrey Pawlikowski
- Marmorstein Laboratory, UPenn
 - Ronen Marmorstein
 - Michael Grasso
 - Adam Olia
 - Gleb Bazilevsky
- HTSC, UPenn
 - David Schultz